Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Download PDF Copy

Feb 11 2010

Amicus Therapeutics (Nasdaq: FOLD) announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida. The Company also presented encouraging data from preclinical studies evaluating the combination of pharmacological chaperones and enzyme replacement therapy (ERT) for Fabry disease and Pompe disease as well as from preclinical studies examining the use of pharmacological chaperones for the treatment of Parkinson's disease.

SOURCE Amicus Therapeutics

Posted in: Drug Trial News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Can psychedelics break compulsive eating habits in obesity?

Can psychedelics break compulsive eating habits in obesity?

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

Sex-specific mitochondrial marker deficiencies linked to early cognitive dysfunction in Alzheimer’s disease

Sex-specific mitochondrial marker deficiencies linked to early cognitive dysfunction in Alzheimer’s disease

Scientists stop long-COVID symptoms in mice using a new antiviral compound

Scientists stop long-COVID symptoms in mice using a new antiviral compound

Can folic acid prevent or promote breast cancer? It depends on dose and DNA

Can folic acid prevent or promote breast cancer? It depends on dose and DNA

Neurofilament light as a translational biomarker from preclinical drug discovery to clinical application

Neurofilament light as a translational biomarker from preclinical drug discovery to clinical application

Does smoking increase chronic kidney disease risk?

Does smoking increase chronic kidney disease risk?

New antiviral compounds show broad protection against COVID-19 variants

New antiviral compounds show broad protection against COVID-19 variants

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation